Adjuvant Osimertinib for Lung Cancer
(TARGET Trial)

Recruiting in Palo Alto (17 mi)

+55 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: AstraZeneca

Stay on Your Current Meds

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?This trial is testing osimertinib, a lung cancer drug, in patients with specific genetic changes in their cancer. It aims to see if the drug can help prevent cancer from returning after surgery.

Eligibility Criteria

Adults with a confirmed diagnosis of non-squamous NSCLC, who have had complete surgical removal of the tumor and are in stage II-IIIB. They must have specific EGFR mutations, be fully recovered from surgery, not pregnant or breastfeeding, using effective contraception if applicable, and without a history of certain heart conditions or other cancers.

Inclusion Criteria

I can carry out all my usual activities without help.

You have had a scan of your brain using MRI or contrast CT.

I have fully recovered from any surgery and its follow-up treatments.

+7 more

Exclusion Criteria

I do not have any major heart issues or a family history of sudden heart-related deaths.

I am not taking strong CYP3A4 inducers for the last 3 weeks.

I have only had minor lung surgery.

+6 more

Participant Groups

The trial is testing the effectiveness and safety of osimertinib for patients with EGFRm positive stage II-IIIB NSCLC after full tumor resection. It may include those who've had adjuvant chemotherapy. The focus is on long-term outcomes over five years.

1Treatment groups

Experimental Treatment

Group I: OsimertinibExperimental Treatment1 Intervention

Participants will receive osimertinib (AZD9291).